Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations

Annals of Surgery

Volumn 236, Issue 5, 2002, Pages 570-575

  Fitze, Guido ^a   Schierz, Mandy ^a   Bredow, Jan ^a   Saeger, Hans D ^a   Roesner, Dietmar ^a   Schackert, Hans K ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET;

ADOLESCENT; ADULT; ARTICLE; CELL HYPERPLASIA; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PENETRANCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTO ONCOGENE; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION;

ADULT; CARCINOMA, MEDULLARY; CHILD; CODON; DROSOPHILA PROTEINS; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PENETRANCE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0036829504     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200211000-00006     Document Type: Article

References (27)

1. Eng C, Mulligan LM. Mutation of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 1997; 9:97-109.
2. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-RET proto-oncogene. Nature 1996; 381:785-789.
3. Lin LFH, Doferty DH, Lile JD, et al. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260:1130-1132.
4. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial cell line-derived neurotrophic factor. Nature 1996; 384:467-470.
5. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. Neuron 1998; 21:1291-1302.
6. Mulligan LM, Kwok JBJ, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-460.
7. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993; 2:851-856.
8. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367:375-376.
9. Borrello MG, Smith DP, Pasini B, et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995; 11:2419-2427.
10. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995; 267:381-383.
11. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995; 10:2415-2419.
12. Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the RET protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998; 83:770-774.
13. Pasini A, Geneste O, Legrand P, et al. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997; 15:393-402.
14. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 200:237-250.
15. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. Wold J Surg 1998; 22:744-751.
16. Schuffenecker I, Ginet N, Goldgar D, et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 1997; 60:233-237.
17. Ceccherini I, Hofstra RMW, Luo Y, et al. DNA polymorphisms and condition for SSCP analysis of the 20 exons of the ret protooncogene. Oncogene 1994; 9:3025-3029.
18. Mulligan LM, Eng C, Attie T, et al. Diverse phenotype associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994; 3:2163-2167.
19. Fitze G, Schreiber M, Kuhlisch E, et al. Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease. Am J Hum Genet 1999; 65:1469-1473.
20. Gimm O, Dralle H. C-cell cancer: Prevention and treatment. Langenbeck's Arch Surg 1999; 384:16-23.
21. Hinze R, Holzhausen HJ, Gimm O, et al. Primary heredity medullary thyroid carcinoma: C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch 1998; 433:203-208.
22. Hotz HG, Runkel NSF, Frank-Raue K, et al. Prophylactic thyroidectomy in MEN IIA: Does the calcitonin level correlate with tumor spread? Langenbeck's Arch Surg 1998; 383:170-173.
23. Marsh DJ, McDowall D, Hyland VJ, et al. The identification of false-positive response to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996; 44:213-220.
24. Marsh DJ, Andrew SD, Eng C, et al. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996; 56:1241-1243.
25. Seri M, Yin L, Barone V, et al. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 1997; 9:243-249.
26. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: Is prophylactic thyroidectomy indicated? Surgery 2000; 128:1052-1058.
27. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlation in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties. J Clin Endocrinol Metab 2001; 86:1104-1109.